Mary K. Moreland, Executive Vice President of Abbott Laboratories, filed a Form 4 on November 6, 2026, disclosing a sale of common shares on November 5, 2026.
Key Highlights
- Reporting person: Mary K. Moreland, Executive Vice President of Abbott Laboratories (NYSE:ABT)
- Transaction: Disposition (code S) of 3,500 common shares without par value on November 5, 2026, at $116 per share
- Direct holdings after transaction: 100,791 common shares held directly
- Indirect holdings: 17,345 common shares held indirectly through the Abbott Laboratories Stock Retirement Trust, as of November 5, 2026
- Filing date: November 6, 2026, signed by Jessica H. Paik as Attorney-in-Fact for Moreland
Moreland's November 2026 Share Disposition at Abbott Laboratories
According to the Form 4 filed with the U.S. Securities and Exchange Commission, Mary K. Moreland, identified in the filing as an Executive Vice President of Abbott Laboratories, disposed of 3,500 common shares without par value on November 5, 2026. The transaction was recorded under code "S" at a price of $116 per share. The filing does not indicate whether this sale was made pursuant to a Rule 10b5-1 trading plan, as the corresponding checkbox on the form was not checked.
Following the reported transaction, the filing states that Moreland directly holds 100,791 common shares. In addition, the filing discloses an indirect beneficial ownership of 17,345 common shares through the Abbott Laboratories Stock Retirement Trust, with the filing noting this figure represents the balance in that trust as of November 5, 2026. No derivative securities transactions were reported in Table II of the filing.
The Form 4 was filed on November 6, 2026, and signed by Jessica H. Paik as Attorney-in-Fact on behalf of Mary K. Moreland. The filing was submitted as a form filed by one reporting person and is not an amendment to a prior filing.
What Was Disclosed
Abbott Laboratories Executive Vice President Mary K. Moreland disclosed the sale of 3,500 common shares at $116 each on November 5, 2026. After the transaction, she directly held 100,791 shares, with an additional 17,345 shares held indirectly via the Abbott Laboratories Stock Retirement Trust.



Please wait processing your request...